TP53 and osteosarcoma: Loss of activity of several tumor suppressors by genetic alterations (including TP53 and Retinoblastoma gene RB1 mutations) is a common feature of osteosarcoma tumors, but at present, the study of genetic abnormalities does not provide opportunities to aid the clinical management of this disease.